Catalyst Wire Dossier Catalyst Wire Dossier

Chimeric Antigen Receptor T Lymphocytes

CAR-T cells · Beijing Immunochina Medical Science & Technology Co., Ltd.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Chimeric Antigen Receptor T Lymphocytes, covering 2021-11-11 to 2021-11-11. Get the full timeline:

Most recent: Clinical Trial Update: Safety and Efficacy of Chimeric Antigen Receptor T Lymphocytes for Patients With Intermediate and Advanced Tumors [Phase 1, Phase 2]

See pricing